Av. Ernest Lluch 32
22 articles with Minoryx Therapeutics
Minoryx Therapeutics announces that its lead drug candidate, leriglitazone (MIN-102), has been granted Orphan Drug Designation in Friedreich’s Ataxia by the US Food and Drug Administration (FDA).
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
10/10/2019Companies from across the globe provide updates on their business and pipelines.
Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia
Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule
Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
Minoryx Therapeutics announces that the first patient has been dosed with its lead candidate, leriglitazone, in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.
Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, announces that it has appointed Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.
Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to launch a phase 2 clinical trial in Friedreich’s Ataxia with its lead candidate, MIN-102.
Minoryx Therapeutics opens Belgian subsidiary that will lead important development activities
Minoryx Therapeutics announces early completion of patient randomization in the ADVANCE trial: a phase 2/3 clinical study of MIN-102 in X-ALD patients
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has completed patient randomization of its phase 2/3 clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN). The trial enrolled adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).
New investment will allow indication expansion of Minoryx’s lead compound, MIN-102
Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE)
ADVANCE trial recruitment is progressing rapidly in Europe with over 50 percent X-ALD patients enrolled
Inthera Bioscience AG Expands Management Team with Seasoned Professionals and Secures €4.7 Million Second Tranche of €9.6 Million Series A Financing
Inthera Bioscience AG today announced that three senior Pharma and Biotech Industry members joined its management team.
Minoryx Therapeutics Announces the Dosing of First Patient in ADVANCE, a Phase II/III Clinical Study of MIN-102 in Patients With Adrenomyeloneuropathy (AMN)
The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy.